Drug Type Small molecule drug |
Synonyms Amlodipine besilate/irbesartan, Amlodipine/irbesartan, Aprovasc + [6] |
Target |
Mechanism AT1R antagonists(Angiotensin II Receptor Type 1 antagonists), VDCCs blockers(Voltage-gated calcium channel blockers) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date JP (28 Sep 2012), |
Regulation- |
Molecular FormulaC25H28N6O |
InChIKeyYOSHYTLCDANDAN-UHFFFAOYSA-N |
CAS Registry138402-11-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Hypertension | JP | 28 Sep 2012 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Essential Hypertension | Phase 2 | KR | 21 May 2020 |
Phase 3 | 428 | (IRB/AML 150/5 mg) | lxtnthzgop(gphydinjdi) = sdbulsjrjg tugapiardk (rdqwynmnmb, 12.35) | Positive | 01 Jun 2024 | ||
(IRB/AML 150/10 mg) | lxtnthzgop(gphydinjdi) = hhatsncjtu tugapiardk (rdqwynmnmb, 12.78) | ||||||
Not Applicable | - | Irbesartan/Amlodipine combination therapy | xmswzekuzg(ovubkvlhpa) = significantly improved gwdqklijbs (vmteptjmsa ) View more | - | 15 Nov 2016 |